Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cutaneous paraneoplastic syndromes in solid tumors

R Kurzrock1, P R Cohen

  • 1Department of Clinical Investigation, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

The American Journal of Medicine
|December 1, 1995
PubMed
Summary

Cutaneous paraneoplastic syndromes are skin changes linked to hidden cancers. Recognizing these diverse dermatologic signs is crucial for early cancer detection and prognosis in patients with solid tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.

ESMO open·2026
Same author

Interleukin-2 transcriptomic expression correlates with prolonged survival and with GNAS alterations in patients with advanced cancers.

ESMO open·2026
Same author

DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).

ESMO open·2025
Same author

The best management for most patients with incurable cancer is on a clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Area of Science:

  • Dermatology
  • Oncology
  • Internal Medicine

Background:

  • Cutaneous paraneoplastic syndromes (CPS) are dermatologic manifestations associated with underlying malignancies.
  • These syndromes can present diverse clinical features affecting the skin, mucous membranes, hair, and nails.
  • Their presence often indicates a significant underlying oncologic process, particularly in solid tumors.

Purpose of the Study:

  • To review the clinical presentations, pathophysiology, and oncologic significance of CPS in patients with solid tumors.
  • To highlight the importance of recognizing CPS as potential early indicators of occult cancers.
  • To emphasize the prognostic implications of CPS in cancer management.

Main Methods:

  • A comprehensive literature search was conducted using MEDLINE.

Related Experiment Videos

  • Relevant studies on cutaneous paraneoplastic syndromes and their association with solid tumors were reviewed.
  • Information on clinical manifestations, pathophysiology, and outcomes was synthesized.

    • Main Results:

    • Diverse CPS were identified, including musculoskeletal disorders, reactive erythemas, vascular dermatoses, papulosquamous disorders, and hair growth abnormalities.
    • Clinical manifestations of CPS can precede, coincide with, or follow cancer diagnosis.
    • The presence of CPS is frequently associated with a poor oncologic prognosis.

    Conclusions:

    • CPS are specific skin and mucous membrane abnormalities indicative of an underlying tumor.
    • Awareness of CPS is critical as they may be the initial sign of an undetected malignancy.
    • Patients presenting with CPS require thorough investigation for associated cancers.